# Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

> **NCT02038647** · PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 178 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Alisertib
- **DRUG:** Placebo
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02038647
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-12
- **Primary completion:** 2016-01-03
- **Final completion:** 2017-07-10
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2018-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02038647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02038647, "Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02038647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*